The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.
Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond
Open accessAbstract
The synaptic vesicle glycoprotein SV2A belongs to the major facilitator superfamily (MFS) of transporters and is an integral constituent of synaptic vesicle membranes. SV2A has been demonstrated to be involved in vesicle trafficking and exocytosis, processes crucial for neurotransmission. The anti-seizure drug levetiracetam was the first ligand to target SV2A and displays a broad spectrum of anti-seizure activity in various preclinical models. Several lines of preclinical and clinical evidence, including genetics and protein expression changes, support an important role of SV2A in epilepsy pathophysiology. While the functional consequences of SV2A ligand binding are not fully elucidated, studies suggest that subsequent SV2A conformational changes may contribute to seizure protection. Conversely, the recently discovered negative SV2A modulators, such as UCB0255, counteract the anti-seizure effect of levetiracetam and display procognitive properties in preclinical models. More broadly, dysfunction of SV2A may also be involved in Alzheimer's disease and other types of cognitive impairment, suggesting potential novel therapies for levetiracetam and its congeners. Furthermore, emerging data indicate that there may be important roles for two other SV2 isoforms (SV2B and SV2C) in the pathogenesis of epilepsy, as well as other neurodegenerative diseases. Utilization of recently developed SV2A positron emission tomography ligands will strengthen and reinforce the pharmacological evidence that SV2A is a druggable target, and will provide a better understanding of its role in epilepsy and other neurological diseases, aiding in further defining the full therapeutic potential of SV2A modulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Mechanism of action of clinically approved anti-seizure drugs. Updated and modified from Löscher and Schmidt [151]. Drugs marked with asterisks indicate that these compounds act by multiple mechanims (not all mechanisms shown here). GABA-T GABA aminotransferase, GAT GABA transporter, SV2A synaptic vesicle protein 2A, GABA gamma-aminobutyric acid, NMDA N-methyl-D-aspartate, AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, KCNQ a family of voltage-gated potassium channels (also known as the Kv7 family)](https://figures.cochat.ai/paper-figures/694be75c144240faa7c6d22e54f6d22c/synaptic-vesicle-glycoprotein-2a-ligands-in-the-treatment-of-epilepsy-and-beyond-figure-1.jpg)

![Fig. 3 Effect of LEV on the a MEST in non-kindled rats, and b threshold for secondarily generalized seizures in amygdala-kindled rats. c, d Effect of BRV and SEL on the GST in amygdala-kindled rats. Data are shown as means ± SEM of a 20 non-kindled and b–d 9 fully kindled rats in percentage seizure threshold increase above vehicle control seizure thresholds. Significant differences to control thresholds are indicated by an asterisk (p < 0.05). Note the marked difference in anti-seizure efficacy of LEV in a non-kindled vs. b kindled rats. All drugs also significantly increased the threshold for focal seizures (ADT) in kindled rats. The minimum doses significantly increasing ADT were 1.25 mg/kg (LEV), 0.68 mg/kg (BRV), and 0.0074 mg/kg (SEL). Data on MEST in non-kindled rats are taken from Löscher and Hönack [12], and data on kindled rats are from Potschka and Löscher (unpublished observations). LEV levetiracetam, MEST maximal electroshock seizure threshold, GST generalized seizure threshold, BRV brivaracetam, SEL seletracetam, SEM standard error of the mean, ADT after-discharge threshold, i.p. intraperitoneally](https://figures.cochat.ai/paper-figures/55eccfdd82394651ae3440d7035152a8/synaptic-vesicle-glycoprotein-2a-ligands-in-the-treatment-of-epilepsy-and-beyond-figure-3.jpg)
![Fig. 4 Correlation between the anti-seizure activity of a series of LEV analogs in different epilepsy models and their SV2A in vitro binding affinities. a Genetically sound-susceptible mice; b corneally kindled mice; c rats with spontaneous absence-like EEG seizures from the GAERS strain. SV2A binding affinities pIC50 (−logIC50) were measured in rat brain membranes with the use of [3H]ucb 30889. Protective potencies, based on dose-response studies, are shown as pED50 (−logED50). All correlations were statistically significant (p < 0.01). From Kaminski et al. [20]. LEV levetiracetam, EEG electroencephalogram, GAERS genetical absence epilepsy rats from Strasbourg, SV2A synaptic vesicle protein 2A. ED 50median effective dose, IC 50half maximal inhibitory concentration, pED 50 logED50, pIC 50 logIC50](https://figures.cochat.ai/paper-figures/4f0d15f761d9459d8c5439926e35bb2f/synaptic-vesicle-glycoprotein-2a-ligands-in-the-treatment-of-epilepsy-and-beyond-figure-4.jpg)
![Fig. 5 Schematic representation of the dynamics of SVs at the presynaptic terminal, illustrating detailed mechanism of NT release and synaptic vesicle recycling. SVs are specialized spheroidal membrane structures that traffic along the axon to the presynaptic terminals, where they internalize and store NTs (blue dots). The SV membrane harbors proteins, some of them highly glycosylated (synapsin, synaptotagmin, SV2, and synaptophysin), whose precise sorting is required for an efficient neurotransmission. A magnified view of an SV (top left) shows the main identified vesicular proteins (except for the proton pump). Some SV proteins, such as synapsins or SV2s, come in multiple isoforms. Once SVs are loaded by NTs, a number of processes lead to excocytosis. (1) NT-loaded SVs dock to the presynaptic membrane by interaction of Rab3 with the RIM protein. Docking displays the SVs in close contact with the SNARE ternary complex (syntaxin 1, SNAP25, and VAMP) and SNARE effectors (MUNCs). (2) Preactivation (priming). In response to increased presynaptic concentrations of Ca2+, sensed by synaptophysin, proteins of the complex change conformation, inducing SVs to fuse with the plasma membrane and release their contents into the synaptic cleft. (3) Fusion/release. Subsequently, empty SVs undergo coating with clathrin polymers, and dynamin-driven scission from plasma membrane. (4) Coating/scission allows SV membrane proteins to be recycled. SV2s are thought to be involved in several of these processes, including calcium-dependent exocytosis, NT loading/retention in synaptic vesicles, and synaptic vesicle priming, as well as transport of vesicle constituents. Updated and modified from Rossetto et al. [23]. SVs synaptic vesicles, NT neurotransmitter, SV2 synaptic vesicle protein-2, Syt synaptotagmin, VAMP vesicle integral membrane protein, SNARE soluble N-ethylmaleimide-sensitive factor attachment protein receptor, RIM proteins a family of active zone proteins, SNAP25 synaptosomal-associated protein 25, MUNC mammalian uncoordinated proteins, ADP adenosine diphosphate, ATP adenosine triphosphate](https://figures.cochat.ai/paper-figures/f67babb58fbf42a39c0f5376d3d7cc09/synaptic-vesicle-glycoprotein-2a-ligands-in-the-treatment-of-epilepsy-and-beyond-figure-5.jpg)
![Fig. 6 Schematic representation of SV2A. a SV2A is comprised of 2 TM domains (each of which is comprised of 6 TM helices) and three extramembranous domains, namely the amino domain (blue); a long intervening loop spanning region between TM helices 6 and 7 (orange); and an extracellular domain between TM helices 7 and 8 (green). 2D protein topology figure generated using Protter [152]. Models of b inward-open (based on GlpT template) and c outward-open (based on FucP) conformations of the SV2A protein [86] aligned using the numbering system for proteins of the major facilitator superfamily [153]. TM transmembrane, 2D 2-dimensional, SV2A synaptic vesicle protein-2A, GlpT glycerol-3-phosphate transporter, FucP L-fucose-proton symporter](https://figures.cochat.ai/paper-figures/b1bb645587184654a6c1a9e8d0fc52b7/synaptic-vesicle-glycoprotein-2a-ligands-in-the-treatment-of-epilepsy-and-beyond-figure-6.jpg)
![Fig. 7 Characterization of a novel SV2A PET radiotracer [11C]UCB-J in humans. a Axial, coronal and sagittal brain MRI images in a healthy volunteer subject (top row); regional volume of distribution maps (VT) during test (middle row) and retest (bottom row) PET scanning with [11C]UCB-J in the same subject. b Axial and coronal brain MRI images in a patient with temporal lobe epilepsy (top row); standardized uptake value maps (SUV) of [11C]UCB-J in the same subject (bottom row). Arrows show unilateral mesial temporal sclerosis (MTS) seen on MRI (top row) and reduced radioligand binding in the corresponding areas of the right mesial temporal lobe of the same subject (bottom row). From Finnema et al. [55]. SV2A synaptic vesicle protein-2A, PET positron emission tomography, MRI magnetic resonance imaging, SUV standardized uptake value, MTS mesial temporal sclerosis, V T volume of distribution](https://figures.cochat.ai/paper-figures/0632327ab6974cc299df1559444b130b/synaptic-vesicle-glycoprotein-2a-ligands-in-the-treatment-of-epilepsy-and-beyond-figure-7.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Through these convergent actions, SV2A functions as a molecular scaffold that stabilizes presynaptic terminals while postsynaptic strengthening consolidates [175,184,198].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [175]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Across models of stress, epilepsy, and neurodegeneration, modulation of SV2A preserves synaptic structure and maintains transmission after plasticity induction [173,175,199].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [175]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Functionally, SV2A modulation limits the slide from induced plasticity to maladaptive remodeling and relapse-like behavior [175,199,205].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [175]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This places SV2A at the center of synaptic resilience, linking vesicle dynamics to durable circuit integrity in health and disease [173,175,195].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [175]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Levetiracetam restores vesicle fusion fidelity, rescues basal transmission, and normalizes synaptic protein composition, effects that depend on direct SV2A engagement and extend to hippocampal volume and plasticity recovery [173,175,199].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [175]
Experimental — accuracy not yet measured
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Integrative genomics identifies APOE ε4 effectors in Alzheimer's disease
Rhinn, H., Fujita, R., Qiang, L., Cheng, R., Lee, J. H., & Abeliovich, A. (2013) · Nature · doi:10.1038/nature12415 · Cited by 171
RetractedEarly Identification of Refractory Epilepsy
Kwan, P., & Brodie, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002033420503 · Cited by 5,204 · cited 1×
“patients who did not respond to previous ASDs are more likely to demonstrate pharmacoresistance to additional ASD treatment regimens [127, 128].”
BackgroundThe synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610 · cited 2×
“In 2003, the molecular nature of LBS was discovered and identified as the synaptic vesicle glycoprotein 2A (SV2A) [6].”
BackgroundProtter: interactive protein feature visualization and integration with experimental proteomic data
Omasits, U., Ahrens, C. H., Müller, S., & Wollscheid, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt607 · Cited by 1,347 · cited 1×
“2D protein topology figure generated using Protter [152].”
MethodThe neurobiology of antiepileptic drugs
Rogawski, M. A., & Löscher, W. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1430 · Cited by 1,239 · cited 1×
“This involves modulation of voltage-gated ion channels, enhancement of c-aminobutyric acid (GABA)-mediated inhibition, interactions with elements of the synaptic release machinery, or blockade of ionotropic glutamate receptors [4, 5].”
BackgroundSelf-citationThe descriptive epidemiology of epilepsy—A review
Banerjee, P. N., Filippi, D., & Allen Hauser, W. (2009) · Epilepsy Research · doi:10.1016/j.eplepsyres.2009.03.003 · Cited by 929 · cited 1×
“Epilepsy is the most common neurological condition affecting individuals of all ages and a cause of substantial morbidity and mortality [1, 2].”
BackgroundReduction of Hippocampal Hyperactivity Improves Cognition in Amnestic Mild Cognitive Impairment
Bakker, A., Krauss, G. L., Albert, M. S., Speck, C. L., Jones, L. R., Stark, C. E., Yassa, M. A., Bassett, S. S., Shelton, A. L., & Gallagher, M. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.023 · Cited by 908 · cited 2×
“cantly improved [60], substantiating previous experiments with levetiracetam in a rat model of age-related memory loss [61].”
BackgroundResultChang, B. S., & Lowenstein, D. H. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022308 · Cited by 731
Buckley, K., & Kelly, R. B. (1985) · The Journal of cell biology · doi:10.1083/jcb.100.4.1284 · Cited by 712 · cited 1×
“SV2, one of the first synaptic vesicle proteins identified, is a component of all vertebrate synaptic vesicles [25].”
BackgroundNew avenues for anti-epileptic drug discovery and development
Löscher, W., Klitgaard, H., Twyman, R. E., & Schmidt, D. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4126 · Cited by 675
Self-citation
Research works printed but not linked: 2
- Crèvecoeur J, Kaminski R, Rogister B, et al. Expression of synaptic vesicle protein 2C (SV2C) is selectively increased in hippocampal sclerosis with mossy fiber sprouting. Eur J Neurol. 2011;18(Suppl. 2):175.
- Wasterlain C, Suchomelova L, Matagne A, et al. Short-term and long-term effects of brivaracetam in an animal model of status epilepticus. Epilepsia. 2009;50(Suppl. 10):13.
Cited by
Löscher, W., & Klein, P. (2021) · CNS Drugs · doi:10.1007/s40263-021-00827-8 · Cited by 367
“The finding of Löscher and Hönack [32] that levetiracetam is particularly effective in the amygdalakindling model was essential in the further development of this compound, which is now one of the most widely used ASMs [33].”
BackgroundSelf-citationThe Concise Guide to PHARMACOLOGY 2023/24: Transporters
Alexander, S. P. H., Fabbro, D., Kelly, E., Mathie, A. A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Davies, J. A., et al. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16182 · Cited by 163
Bialer, M., Johannessen, S. I., Koepp, M. J., Levy, R. H., Perucca, E., Perucca, P., Tomson, T., & White, H. S. (2020) · Epilepsia · doi:10.1111/epi.16725 · Cited by 149
Löscher, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.730257 · Cited by 153
“However, the typical approach of ASM testing in animal models primarily focuses on drug potency, and not efficacy (Löscher, 2016).”
BackgroundInfluentialSelf-citationThe holy grail of epilepsy prevention: Preclinical approaches to antiepileptogenic treatments
Löscher, W. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.04.011 · Cited by 144
Self-citation
Metadata
- Authors
- Löscher, W., Gillard, M., Sands, Z. A., Kaminski, R. M., & Klitgaard, H.
- Affiliations
- University of Veterinary Medicine Hannover, Foundation (DE)
- UCB Pharma (Belgium) (BE)
- Corresponding author
- Löscher, Wolfgang
- Venue
- CNS Drugs
- Published
- 2016-10-17
- Volume
- 30
- Issue
- 11
- Pages
- 1055-1077
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- PMC
- PMC5078162
- OpenAlex
- W2539233923
- Cited by
- 184
- References
- 163
- Citations by year
- 2026: 20 · 2025: 23 · 2024: 20 · 2023: 12 · 2022: 17 · 2021: 29 · 2020: 20 · 2019: 21 · 2018: 10 · 2017: 11
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- CNS Drugs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion Transport and Channel Regulation
- Keywords
- SV2A, levetiracetam, epilepsy, major facilitator superfamily, vesicle trafficking, exocytosis, neurotransmission, procognitive effects, Alzheimer's disease, cognitive impairment, SV2B, SV2C, druggable targets, antiepileptic drugs
- MeSH terms
- Animals, Anticonvulsants, Epilepsy, Humans, Ligands, Membrane Glycoproteins, Synaptic Vesicles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond. https://app.cochat.ai/papers/10.1007/s40263-016-0384-x
- The paper
- Löscher, W., Gillard, M., Sands, Z. A., Kaminski, R. M., & Klitgaard, H. (2016). Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond. CNS Drugs. https://doi.org/10.1007/s40263-016-0384-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.